• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

胆碱能连接:对精神疾病的影响。

Cholinergic connectivity: it's implications for psychiatric disorders.

机构信息

Department of Psychiatry, The University of Melbourne Parkville, VIC, Australia ; Molecular Psychiatry Laboratories, Florey Institute of Neuroscience and Mental Health Parkville, VIC, Australia.

出版信息

Front Cell Neurosci. 2013 May 3;7:55. doi: 10.3389/fncel.2013.00055. eCollection 2013.

DOI:10.3389/fncel.2013.00055
PMID:23653591
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3642390/
Abstract

Acetylcholine has been implicated in both the pathophysiology and treatment of a number of psychiatric disorders, with most of the data related to its role and therapeutic potential focusing on schizophrenia. However, there is little thought given to the consequences of the documented changes in the cholinergic system and how they may affect the functioning of the brain. This review looks at the cholinergic system and its interactions with the intrinsic neurotransmitters glutamate and gamma-amino butyric acid as well as those with the projection neurotransmitters most implicated in the pathophysiologies of psychiatric disorders; dopamine and serotonin. In addition, with the recent focus on the role of factors normally associated with inflammation in the pathophysiologies of psychiatric disorders, links between the cholinergic system and these factors will also be examined. These interfaces are put into context, primarily for schizophrenia, by looking at the changes in each of these systems in the disorder and exploring, theoretically, whether the changes are interconnected with those seen in the cholinergic system. Thus, this review will provide a comprehensive overview of the connectivity between the cholinergic system and some of the major areas of research into the pathophysiologies of psychiatric disorders, resulting in a critical appraisal of the potential outcomes of a dysregulated central cholinergic system.

摘要

乙酰胆碱在多种精神疾病的病理生理学和治疗中都有涉及,大多数与乙酰胆碱的作用和治疗潜力相关的数据都集中在精神分裂症上。然而,人们很少考虑到胆碱能系统中已有记录的变化所带来的后果,以及这些变化可能如何影响大脑的功能。这篇综述探讨了胆碱能系统及其与内在神经递质谷氨酸和γ-氨基丁酸的相互作用,以及与最能反映精神疾病病理生理学的投射神经递质多巴胺和 5-羟色胺的相互作用。此外,由于最近人们关注通常与炎症相关的因素在精神疾病病理生理学中的作用,因此还将检查胆碱能系统与这些因素之间的联系。通过研究这些系统在疾病中的变化,并从理论上探讨这些变化是否与胆碱能系统中观察到的变化相互关联,将这些界面主要针对精神分裂症进行了论述。因此,这篇综述将全面概述胆碱能系统与精神疾病病理生理学研究的一些主要领域之间的联系,从而对中枢胆碱能系统失调的潜在后果进行批判性评估。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d01/3642390/f5ef7dabdac5/fncel-07-00055-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d01/3642390/200ad9638634/fncel-07-00055-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d01/3642390/4236e12422ab/fncel-07-00055-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d01/3642390/e3b56635f224/fncel-07-00055-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d01/3642390/e9c99ef64a4e/fncel-07-00055-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d01/3642390/f5ef7dabdac5/fncel-07-00055-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d01/3642390/200ad9638634/fncel-07-00055-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d01/3642390/4236e12422ab/fncel-07-00055-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d01/3642390/e3b56635f224/fncel-07-00055-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d01/3642390/e9c99ef64a4e/fncel-07-00055-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d01/3642390/f5ef7dabdac5/fncel-07-00055-g0005.jpg

相似文献

1
Cholinergic connectivity: it's implications for psychiatric disorders.胆碱能连接:对精神疾病的影响。
Front Cell Neurosci. 2013 May 3;7:55. doi: 10.3389/fncel.2013.00055. eCollection 2013.
2
Cholinergic systems and schizophrenia: primary pathology or epiphenomena?胆碱能系统与精神分裂症:原发性病理改变还是副现象?
J Chem Neuroanat. 2001 Jul;22(1-2):53-63. doi: 10.1016/s0891-0618(01)00101-6.
3
Role of the central cholinergic system in the therapeutics of schizophrenia.中枢胆碱能系统在精神分裂症治疗中的作用。
Curr Neuropharmacol. 2008 Sep;6(3):286-92. doi: 10.2174/157015908785777247.
4
[Preliminary research on multi-neurotransmitters' change regulation in 120 depression patients' brains].[120例抑郁症患者大脑中多种神经递质变化规律的初步研究]
Zhongguo Zhong Yao Za Zhi. 2014 Apr;39(8):1516-24.
5
Opposite effects of dopamine and serotonin on resting-state networks: review and implications for psychiatric disorders.多巴胺和血清素对静息态网络的相反影响:综述及对精神障碍的意义。
Mol Psychiatry. 2020 Jan;25(1):82-93. doi: 10.1038/s41380-019-0406-4. Epub 2019 Apr 5.
6
New Targets for Schizophrenia Treatment beyond the Dopamine Hypothesis.超越多巴胺假说的精神分裂症治疗新靶点。
Int J Mol Sci. 2017 Aug 3;18(8):1689. doi: 10.3390/ijms18081689.
7
Network beyond IDO in psychiatric disorders: revisiting neurodegeneration hypothesis.精神障碍中除 IDO 之外的网络:重新审视神经退行性假说。
Prog Neuropsychopharmacol Biol Psychiatry. 2014 Jan 3;48:304-13. doi: 10.1016/j.pnpbp.2013.08.008. Epub 2013 Oct 31.
8
Cholinergic muscarinic M and M receptors as therapeutic targets for cognitive, behavioural, and psychological symptoms in psychiatric and neurological disorders.胆碱能毒蕈碱 M 和 M 受体作为治疗精神和神经疾病认知、行为和心理症状的靶点。
Drug Discov Today. 2019 Dec;24(12):2307-2314. doi: 10.1016/j.drudis.2019.08.009. Epub 2019 Sep 6.
9
Possible involvement of muscarinic receptors in psychiatric disorders: a focus on schizophrenia and mood disorders.毒蕈碱受体在精神障碍中的可能作用:聚焦于精神分裂症和情绪障碍
Curr Mol Med. 2015;15(3):253-64. doi: 10.2174/1566524015666150330144821.
10
[Dysphagia or dysphagias during neuroleptic medication?].[使用抗精神病药物期间的吞咽困难?]
Encephale. 2012 Sep;38(4):351-5. doi: 10.1016/j.encep.2011.07.002. Epub 2011 Oct 11.

引用本文的文献

1
Targeting Neuronal Alpha7 Nicotinic Acetylcholine Receptor Upregulation in Age-Related Neurological Disorders.靶向年龄相关性神经疾病中神经元α7烟碱型乙酰胆碱受体上调
Cell Mol Neurobiol. 2025 Jul 16;45(1):70. doi: 10.1007/s10571-025-01586-6.
2
[Antipsychotic drugs beyond the dopamine D blockade-Xanomeline-trospium as beacon of hope?].[多巴胺D阻断之外的抗精神病药物——占诺美林-曲司氯铵是希望之光吗?]
Nervenarzt. 2025 May;96(3):304-308. doi: 10.1007/s00115-025-01830-w. Epub 2025 Apr 22.
3
The effect of scopolamine on memory and attention: a systematic review and meta-analysis.

本文引用的文献

1
Differential expression of exosomal microRNAs in prefrontal cortices of schizophrenia and bipolar disorder patients.精神分裂症和双相情感障碍患者前额叶皮质中外泌体 microRNAs 的差异表达。
PLoS One. 2013;8(1):e48814. doi: 10.1371/journal.pone.0048814. Epub 2013 Jan 30.
2
A randomized exploratory trial of an α-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia.一项关于 α-7 烟碱型乙酰胆碱受体激动剂(TC-5619)治疗精神分裂症认知障碍的随机探索性试验。
Neuropsychopharmacology. 2013 May;38(6):968-75. doi: 10.1038/npp.2012.259. Epub 2012 Dec 18.
3
Antidepressant effects of the muscarinic cholinergic receptor antagonist scopolamine: a review.
东莨菪碱对记忆和注意力的影响:一项系统评价与荟萃分析。
Eur Psychiatry. 2025 Apr 8;68(1):e50. doi: 10.1192/j.eurpsy.2025.2446.
4
Does KarXT (xanomeline-trospium) represent a novel approach to schizophrenia management? A GRADE-assessed systematic review and meta-analysis of randomized controlled clinical trials.KarXT( xanomeline - trospium)是否代表了精神分裂症治疗的新方法?一项基于GRADE评估的随机对照临床试验的系统评价和荟萃分析。
BMC Psychiatry. 2025 Mar 31;25(1):309. doi: 10.1186/s12888-025-06696-5.
5
Xanomeline-trospium (Cobenfy) for Schizophrenia: A Review of the Literature.用于治疗精神分裂症的占诺美林-曲司氯铵(Cobenfy):文献综述
Clin Psychopharmacol Neurosci. 2025 Feb 28;23(1):2-14. doi: 10.9758/cpn.24.1253. Epub 2024 Nov 13.
6
Neurostructural changes in schizophrenia and treatment-resistance: a narrative review.精神分裂症及治疗抵抗中的神经结构变化:一篇叙述性综述。
Psychoradiology. 2024 Sep 6;4:kkae015. doi: 10.1093/psyrad/kkae015. eCollection 2024.
7
EEG-based Signatures of Schizophrenia, Depression, and Aberrant Aging: A Supervised Machine Learning Investigation.基于脑电图的精神分裂症、抑郁症和异常衰老特征:一项监督式机器学习研究。
Schizophr Bull. 2025 May 8;51(3):804-817. doi: 10.1093/schbul/sbae150.
8
The New Horizon of Antipsychotics beyond the Classic Dopaminergic Hypothesis-The Case of the Xanomeline-Trospium Combination: A Systematic Review.超越经典多巴胺能假说的抗精神病药物新视野——占诺美林-曲司氯铵组合的案例:一项系统综述
Pharmaceuticals (Basel). 2024 May 9;17(5):610. doi: 10.3390/ph17050610.
9
The Difficult Path to the Discovery of Novel Treatments in Psychiatric Disorders.精神障碍新型治疗方法发现的艰难之路。
Adv Neurobiol. 2023;30:255-285. doi: 10.1007/978-3-031-21054-9_11.
10
Dopamine, Immunity, and Disease.多巴胺、免疫与疾病
Pharmacol Rev. 2023 Jan;75(1):62-158. doi: 10.1124/pharmrev.122.000618. Epub 2022 Dec 8.
东莨菪碱作为毒蕈碱型乙酰胆碱受体拮抗剂的抗抑郁作用:综述。
Biol Psychiatry. 2013 Jun 15;73(12):1156-63. doi: 10.1016/j.biopsych.2012.09.031. Epub 2012 Nov 28.
4
Role of BDNF/TrkB signaling in antidepressant-like effects of a group II metabotropic glutamate receptor antagonist in animal models of depression.脑源性神经营养因子/TrkB 信号在 II 型代谢型谷氨酸受体拮抗剂抗抑郁作用中的作用:动物模型研究。
Behav Brain Res. 2013 Feb 1;238:48-52. doi: 10.1016/j.bbr.2012.10.023. Epub 2012 Oct 23.
5
Treatment of Visual Hallucinations in Schizophrenia by Acetylcholinesterase Inhibitors: a case report.乙酰胆碱酯酶抑制剂治疗精神分裂症视觉幻觉:一例报告
Iran J Psychiatry. 2011 Fall;6(4):161-3.
6
The neurodevelopmental hypothesis of schizophrenia: convergent clues from epidemiology and neuropathology.精神分裂症的神经发育假说:来自流行病学和神经病理学的趋同线索。
Psychiatr Clin North Am. 2012 Sep;35(3):571-84. doi: 10.1016/j.psc.2012.06.002. Epub 2012 Jul 15.
7
Role of M3 mAChR in in vivo and in vitro models of LPS-induced inflammatory response.M3 mAChR 在 LPS 诱导的炎症反应体内和体外模型中的作用。
Int Immunopharmacol. 2012 Nov;14(3):320-7. doi: 10.1016/j.intimp.2012.07.020. Epub 2012 Aug 19.
8
Neuropsychiatric symptoms in mild dementia with lewy bodies and Alzheimer's disease.路易体痴呆和阿尔茨海默病轻度认知障碍的神经精神症状。
Dement Geriatr Cogn Disord. 2012;34(1):1-6. doi: 10.1159/000339590. Epub 2012 Jul 31.
9
Muscarinic M4 receptors regulate GABAergic transmission in rat tuberomammillary nucleus neurons.毒蕈碱型 M4 受体调节大鼠乳头体核神经元 GABA 能传递。
Neuropharmacology. 2012 Nov;63(6):936-44. doi: 10.1016/j.neuropharm.2012.07.007. Epub 2012 Jul 22.
10
Different changes in cortical tumor necrosis factor-α-related pathways in schizophrenia and mood disorders.皮质肿瘤坏死因子-α相关通路在精神分裂症和心境障碍中的不同变化。
Mol Psychiatry. 2013 Jul;18(7):767-73. doi: 10.1038/mp.2012.95. Epub 2012 Jul 17.